B cell subsets are associated with durable responses in distinct cancer types after immune checkpoint inhibition

B cells are a critical arm of the adaptive immune system. However, the impact of B cells and antibody responses on overall cancer survival remains understudied. Here, we report results from a prospective randomized phase 2 trial of 106 patients treated with immune checkpoint inhibitors (ICIs) and identify that B cell antibody responses are associated with exceptional complete responses to ICI in certain cancer types. To further dissect the impact of B cell subtypes, we generated a comprehensive single-cell RNA sequencing database of intratumoral B cells in 12 tumor types from 152 patients. We found a context-dependent role for B cells, in which they are beneficial in certain cancer types and potentially unfavorable in others, with germinal center and memory B cells enriched in favorable prognosis cohorts and immunoglobulin A-positive plasma cells enriched in unfavorable prognosis cohorts. Depletion of B cells using rituximab in patients before surgery affected intratumoral T cell frequency and diversity. Furthermore, we show that B cells improve long-term overall survival even when T cell infiltrates are already high, indicating that a coordinated dual-arm T cell and B cell adaptive immune response is key to long-term tumor control. Overall, these results demonstrate that B cells and antibody responses in the proper context play an important role in durable complete responses in multiple tumor types.

Authors

Institutions

Publication Details

Journal
Science Translational Medicine
Published
2026-10-28
DOI
https://doi.org/10.1126/scitranslmed.adv7928
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

B cell subsets are associated with durable responses in distinct cancer types after immune checkpoint inhibition

Ezra E.W. Cohen, Arno James Mundt, Jason Keith Sicklick, Elizabeth Weihe et al.
1 links
Science Translational Medicine
Cancer Immunotherapy and Biomarkers
article

B cell subsets are associated with durable responses in distinct cancer types after immune checkpoint inhibition

Ezra E.W. Cohen, Arno James Mundt, Jason Keith Sicklick, Elizabeth Weihe, Joseph A. Califano, Christopher J. Kane, Jamillah Murtadha, Hitendra Patel, Christina A. M. Jamieson, Jorge Silvio Gutkind, Kathryn Ann Gold, Jingjing Zou, Sayuri Miyauchi, Sangwoo S. Kim, Loren K. Mell, Rebecca Arielle Shatsky, Gregory P. Botta, P. Dominick Sanders, Razelle Kurzrock, Susan M. Kaech, Andrew B. Sharabi, Natalie E. Quach, James Don Murphy, Sandip Pravin Patel, Karen S. Messer, Roy S, Sarah G Boles, Minya Pu, Lin Zhang, Stephen T. Ryan, Riley N. Jones, Emily I. Pittman, Shumei Kato, Diane Simeone
article en

Abstract

B cells are a critical arm of the adaptive immune system. However, the impact of B cells and antibody responses on overall cancer survival remains understudied. Here, we report results from a prospective randomized phase 2 trial of 106 patients treated with immune checkpoint inhibitors (ICIs) and identify that B cell antibody responses are associated with exceptional complete responses to ICI in certain cancer types. To further dissect the impact of B cell subtypes, we generated a comprehensive single-cell RNA sequencing database of intratumoral B cells in 12 tumor types from 152 patients. We found a context-dependent role for B cells, in which they are beneficial in certain cancer types and potentially unfavorable in others, with germinal center and memory B cells enriched in favorable prognosis cohorts and immunoglobulin A-positive plasma cells enriched in unfavorable prognosis cohorts. Depletion of B cells using rituximab in patients before surgery affected intratumoral T cell frequency and diversity. Furthermore, we show that B cells improve long-term overall survival even when T cell infiltrates are already high, indicating that a coordinated dual-arm T cell and B cell adaptive immune response is key to long-term tumor control. Overall, these results demonstrate that B cells and antibody responses in the proper context play an important role in durable complete responses in multiple tumor types.

Science Translational MedicineVol. 18(873)
Salk Institute for Biological Studies (US), Medical College of Wisconsin (US), University of California San Diego (US), Moores Cancer Center (US)
Varian Medical Systems, National Institutes of Health
Good health and well-being
Openalex Percentile: Top 16%
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon